SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY
PODDUBNYY, D., A. DEODHAR, X. BARALIAKOS, R. BLANCO, Eva DOKOUPILOVÁ et. al.
SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM THE PREVENT STUDY
Authors
PODDUBNYY, D., A. DEODHAR, X. BARALIAKOS, R. BLANCO, Eva DOKOUPILOVÁ, S. HALL, A. KIVITZ, M.G.H. VAN DE SANDE, A. STEFANSKA, P. PERTEL, H. RICHARDS and J. BRAUN
Edition
2021
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Axial spondyloarthritis (axSpA) is an inflammatory disease characterised by chronic back pain, and it comprises radiographic axSpA and non-radiographic axSpA (nr-axSpA).1 Secukinumab (SEC) 150 mg, with (LD) or without loading (NL), dose significantly improved the signs and symptoms of patients with nr-axSpA in the PREVENT (NCT02696031) study through Week 52.